Medtronic reports first quarter fiscal 2026 financial results

11th quarter in a row of mid-single digit organic revenue growth; poised to accelerate growth galway, ireland , aug. 19, 2025 /prnewswire/ -- medtronic plc (nyse: mdt), a global leader in healthcare technology, today announced financial results for its first quarter (q1) of fiscal year 2026 (fy26), which ended july 25, 2025. key highlights revenue of $8.6 billion, adjusted revenue of $8.5 billion, increased 8.4% as reported and 4.8% organic gaap diluted eps of $0.81 increased 1%; non-gaap diluted eps of $1.26 increased 2% company raises fy26 eps guidance; reiterates fy26 organic revenue growth guidance cardiac ablation solutions revenue increased nearly 50%, including 72% in the us, on strength of pulsed field ablation (pfa) products u.s. centers for medicare & medicaid services (cms) posted proposed national coverage determination (ncd) for the symplicity spyral™ system for hypertension; final ncd expected on or before october 8, 2025 received ce mark for ligasure™ ras vessel-sealing technology on hugo™ robotic-assisted surgery (ras) system "we delivered another consistent quarter of mid-single digit organic revenue growth, with broad strength from several innovative product categories, including pulsed field ablation, transcatheter valves, neuromodulation, diabetes, and leadless pacing," said geoff martha, medtronic chairman and chief executive officer.
MDT Ratings Summary
MDT Quant Ranking